This webcast features: Joe Ferraiolo, Associate Director, Bioanalytics Applications, C Technologies, a Repligen Company Analytical technologies play a crucial role in accelerating gene therapy speed to market. Dilution steps during protein and DNA quantitation measurements represent the single highest source of accuracy and precision errors. The SoloVPE® device provides a dilution-free workflow that saves time, reduces deviations, and facilitates multisite alignment. Multiple case studies from major biopharmaceutical companies describe execution in process development, analytical labs, and directly on good manufacturing…
Friday, August 21, 2020 Daily Archives
CDMO deals and investments from AGC, Avid, and Fujifilm
New deals inked by AGC Biologics, Avid Bioservices, and Therapure, while Fujifilm breaks ground in Texas. Welcome to Friday’s CDMO round-up. AGC Biologics has been contracted by Japan’s Ono Pharmaceutical for the manufacture of clinical materials. Details are scant but the agreement marks the latest deal announced by the contract development and manufacturing organization (CDMO) in recent months. Since the coronavirus pandemic began, AGC has been named as one of the manufacturers of Novavax’s COVID-19 vaccine candidate NVX-CoV2373; recently said…
Agilent predicts $750 million global oligo market by 2025 and ups capacity
Agilent Technologies has announced plans to more than double nucleic acid-based drug production capacity at its facility in Frederick, Colorado. The research, development and manufacturing company said it will invest $150 million to add 25,000 square feet of capacity. Agilent cited the growing market for “oligos†as the driver for the investment, predicting it will grow in double digits and be worth more than $750 million by 2025. Sam Raha, president of Agilent’s Diagnostics and Genomics Group, said, “Adding this higher-volume…